Rafael Holdings Inc (traded under the ticker RFL on the New York Stock Exchange) does not pay dividends to its common shareholders. As a clinical-stage biotechnology and pharmaceutical holding company focused on drug development and early-stage medical ventures, the organization retains and reinvests its capital resources to fund ongoing research, clinical trials, and operational growth rather than distributing regular income payouts to investors.